Literature DB >> 19074114

The treatment of adults with acute lymphoblastic leukemia.

Adele K Fielding1, Adele Fielding.   

Abstract

Despite the relatively low incidence of acute lymphoblastic leukemia (ALL) in adults, large national and international collaborations have recently improved our understanding of how to treat ALL in adults. This article documents and examines the current evidence base for a "state of the art" therapy in both Philadelphia chromosome-negative and -positive adult ALL. The article comments upon areas of therapeutic debate, such as the role of bone marrow transplantation. In particular, the controversial subject of whether the superior outcome seen in younger patients is predicated on disease biology or therapeutic strategy is examined closely. Promising approaches under development are also discussed.

Entities:  

Mesh:

Year:  2008        PMID: 19074114     DOI: 10.1182/asheducation-2008.1.381

Source DB:  PubMed          Journal:  Hematology Am Soc Hematol Educ Program        ISSN: 1520-4383


  13 in total

1.  Factors associated with durable EFS in adult B-cell ALL patients achieving MRD-negative CR after CD19 CAR T-cell therapy.

Authors:  Kevin A Hay; Jordan Gauthier; Alexandre V Hirayama; Jenna M Voutsinas; Qian Wu; Daniel Li; Ted A Gooley; Sindhu Cherian; Xueyan Chen; Barbara S Pender; Reed M Hawkins; Aesha Vakil; Rachel N Steinmetz; Gary Schoch; Aude G Chapuis; Brian G Till; Hans-Peter Kiem; Jorge D Ramos; Mazyar Shadman; Ryan D Cassaday; Utkarsh H Acharya; Stanley R Riddell; David G Maloney; Cameron J Turtle
Journal:  Blood       Date:  2019-02-06       Impact factor: 22.113

Review 2.  Pharmacotherapeutic advances in the treatment of acute lymphoblastic leukaemia in adults.

Authors:  Mark R Litzow
Journal:  Drugs       Date:  2011-03-05       Impact factor: 9.546

3.  Adipose tissue attracts and protects acute lymphoblastic leukemia cells from chemotherapy.

Authors:  Rocky Pramanik; Xia Sheng; Brian Ichihara; Nora Heisterkamp; Steven D Mittelman
Journal:  Leuk Res       Date:  2013-01-17       Impact factor: 3.156

Review 4.  Novel targets for treatment of adult acute lymphocytic leukemia.

Authors:  Margaret T Kasner
Journal:  Curr Hematol Malig Rep       Date:  2010-10       Impact factor: 4.213

5.  Emerging pharmacotherapies for adult patients with acute lymphoblastic leukemia.

Authors:  Lydia Lee; Adele K Fielding
Journal:  Clin Med Insights Oncol       Date:  2012-01-22

6.  Application of the whole-transcriptome shotgun sequencing approach to the study of Philadelphia-positive acute lymphoblastic leukemia.

Authors:  I Iacobucci; A Ferrarini; M Sazzini; E Giacomelli; A Lonetti; L Xumerle; A Ferrari; C Papayannidis; G Malerba; D Luiselli; A Boattini; P Garagnani; A Vitale; S Soverini; F Pane; M Baccarani; M Delledonne; G Martinelli
Journal:  Blood Cancer J       Date:  2012-03-09       Impact factor: 11.037

7.  Survival of adults with acute lymphoblastic leukemia in Germany and the United States.

Authors:  Dianne Pulte; Lina Jansen; Adam Gondos; Alexander Katalinic; Benjamin Barnes; Meike Ressing; Bernd Holleczek; Andrea Eberle; Hermann Brenner
Journal:  PLoS One       Date:  2014-01-27       Impact factor: 3.240

8.  Targeting Suppressor of Variegation 3-9 Homologue 2 (SUV39H2) in Acute Lymphoblastic Leukemia (ALL).

Authors:  Martin Mutonga; Kenji Tamura; Gregory Malnassy; Noreen Fulton; Amanda de Albuquerque; Ryuji Hamamoto; Wendy Stock; Yusuke Nakamura; Houda Alachkar
Journal:  Transl Oncol       Date:  2015-10       Impact factor: 4.243

9.  Management and treatment of relapsed or refractory Ph(-) B-precursor ALL: a web-based, double-blind survey of EU clinicians.

Authors:  Deborah Saltman; Arie Barlev; Divyagiri Seshagiri; Ioannis Katsoulis; Vincent Lin; Beth Barber
Journal:  BMC Cancer       Date:  2015-10-24       Impact factor: 4.430

10.  Eye on the B-ALL: B-cell receptor repertoires reveal persistence of numerous B-lymphoblastic leukemia subclones from diagnosis to relapse.

Authors:  R J M Bashford-Rogers; K A Nicolaou; J Bartram; N J Goulden; L Loizou; L Koumas; J Chi; M Hubank; P Kellam; P A Costeas; G S Vassiliou
Journal:  Leukemia       Date:  2016-05-23       Impact factor: 11.528

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.